BioNexus Gene Lab Corp — Form SCHEDULE 13D
Filed August 14, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Tan Lee Su-Leng filed a Schedule 13D disclosing acquisition of beneficial ownership in BioNexus Gene Lab Corp (market value ~$4.8M). The filing was dated 2026-08-14. Specific share count, percentage ownership, purchase price, and transaction details are not provided in the metadata extracted; the actual document content would contain these particulars in Item 4 (Amount of Securities Acquired) and Item 5 (Source and Amount of Funds).
Why this rating
Schedule 13D is routine disclosure of 5%+ ownership. Without specific share count/% data visible, cannot assess materiality precisely; if stake is modest relative to float, event is administrative.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.